1. Stocks
    2. /
  2. Mesoblast Limited (ASX: MSB)
    3. /

Mesoblast Limited (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Mesoblast Limited (ASX: MSB)
    Latest News

    Multi-ethnic people looking at camera sitting at public place screaming, shouting and feeling overjoyed about their windfall, good news or sports victory.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a slightly sour end to the trading week this Friday.

    Read more »

    A young woman holding her phone smiles broadly and looks excited, after receiving good news.
    Share Gainers

    Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today

    | James Mickleboro

    These shares are ending the week strongly. But why?

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Healthcare Shares

    Why are Mesoblast shares jumping 10% to a 52-week high?

    | James Mickleboro

    This biotech is hitting new highs on Friday. Let's find out why.

    Read more »

    a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors were in a good mood today.

    Read more »

    woman testing substance in laboratory dish, csl share price
    Share Market News

    After a 73% surge this ASX healthcare share looks far from done

    | Marc Van Dinther

    Brokers are upbeat, and some see possible gains of 90% in 2026.

    Read more »

    Man looking happy and excited as he looks at his mobile phone.
    Share Gainers

    Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today

    | James Mickleboro

    These shares are having a good session on Tuesday. Let's see why.

    Read more »

    research with microscope
    Healthcare Shares

    This ASX healthcare stock just changed its debt. Here's why it matters

    | Aaron Teboneras

    Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

    Read more »

    Ten happy friends leaping in the air outdoors.
    Opinions

    My top 10 ASX stocks to buy for 2026

    | Samantha Menzies

    These are my top picks for 2026.

    Read more »

    Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
    Opinions

    5 ASX shares I'd buy with $10,000 this week

    | Samantha Menzies

    These are the ASX stocks I have my eye on this week.

    Read more »

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Opinions

    Forget CSL shares, I'd buy this booming biotech stock instead

    | Samantha Menzies

    This ASX biotech stock has caught my eye this year.

    Read more »

    A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
    Broker Notes

    These ASX 200 shares could rise 30% to 40%

    | James Mickleboro

    Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

    Read more »

    Four smiling young medics with arms crossed stand outside a hospital.
    Healthcare Shares

    How much further upside is there for Mesoblast shares after soaring 23% in a month?

    | Aaron Bell

    Could FDA approval send this healthcare stock towards further gains?

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Limited

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    Profile

    since

    Note